Horm Metab Res 2022; 54(08): 567-570
DOI: 10.1055/a-1864-8234

Treating Insulin Resistance with Intermittent Personalized Nutrition to Sustain Metabolic Health and Functioning Immune System for Risk Reduction of Viral Diseases Especially COVID-19 and Long-COVID

Markus Rohner
1   EpiGeneticBalance AG, EpiGeneticBalance AG, CH-4310 Rheinfelden, Rheinfelden, Switzerland
Peter E. H. Schwarz
2   Department of Medicine, Carl Gustav Carus, Prevention and Care of Diabetes, Technical University Dresden, Dresden, Germany
3   Paul Langerhans Institute Dresden, German Center for Diabetes Research (DZD), Dresden, Germany
Stefan R. Bornstein
4   Department of Internal Medicine III, University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany
5   Division of Endocrinology, Diabetes and Nutritional Sciences, Faculty of Life Sciences and Medicine, King's College London, London, UK
6   Department of Endocrinology, Diabetology and Clinical Nutrition, University Hospital Zurich (USZ) and University of Zurich (UZH), Zurich, Switzerland
› Author Affiliations


The Covid-19 pandemic has provided new and strong evidence for poor outcomes of viral infection in patients with poor metabolic health. Insulin resistance is at the root of many metabolic conditions and a key driver of their progression as it promotes ineffectual inflammation whilst impairing immune functions. In a vicious circle, insulin resistance facilitates SARS-CoV-2 infection, whilst infection drives insulin resistance. We discuss the underlying mechanisms and explore ways to improve metabolic health and prevent insulin resistance through early detection and targeted nutritional interventions. With proven efficacy in prediabetes, type 2 diabetes, and their cardiovascular and organ complications, as much as non-alcoholic liver disease, we argue to extend such approaches to ensure resilience to the current pandemic and viral challenges beyond.

Publication History

Received: 21 March 2022

Accepted after revision: 30 May 2022

Accepted Manuscript online:
30 May 2022

Article published online:
09 August 2022

© 2022. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

  • References

  • 1 Scuteri A, Laurent S, Cucca F. et al. Metabolic syndrome across Europe: different clusters of risk factors. Eur J Prev Cardiol 2015; 22: 486-491
  • 2 Araujo J, Cai J, Stevens J. Prevalence of optimal metabolic health in American adults: national health and nutrition examination survey 2009-2016. Metab Syndr Relat Disord 2019; 17: 46-52
  • 3 Parcha V, Heindl B, Kalra R. et al. Insulin resistance and cardiometabolic risk profile among nondiabetic American young adults: insights from NHANES. J Clin Endocrinol Metab 2022; 107: e25-e37
  • 4 Gardner JP, Li S, Srinivasan SR. et al. Rise in insulin resistance is associated with escalated telomere attrition. Circulation 2005; 111: 2171-2177
  • 5 Dugani SB, Moorthy MV, Li C. et al. Association of lipid, inflammatory, and metabolic biomarkers with age at onset for incident coronary heart disease in women. JAMA Cardiol 2021; 6: 437-447
  • 6 Chen S, Chen Y, Liu X. et al. Association of insulin resistance with chronic kidney disease in non-diabetic subjects with normal weight. PLoS One 2013; 8: e74058
  • 7 Lee JW, Park SH. Association between depression and nonalcoholic fatty liver disease: contributions of insulin resistance and inflammation. J Affect Disord 2021; 278: 259-263
  • 8 Geraets AFJ, Kohler S, Muzambi R. et al. The association of hyperglycaemia and insulin resistance with incident depressive symptoms over 4 years of follow-up: the Maastricht study. Diabetologia 2020; 63: 2315-2328
  • 9 Ford AH, Flicker L, Hankey GJ. et al. Insulin resistance and depressive symptoms in older men: the health in men study. Am J Geriatr Psychiatry 2015; 23: 872-880
  • 10 Rundek T, Gardener H, Xu Q. et al. Insulin resistance and risk of ischemic stroke among nondiabetic individuals from the northern Manhattan study. Arch Neurol 2010; 67: 1195-2000
  • 11 Nagga K, Gustavsson AM, Stomrud E. et al. Increased midlife triglycerides predict brain beta-amyloid and tau pathology 20 years later. Neurology 2018; 90: e73-e81
  • 12 Sung H, Siegel RL, Rosenberg PS. et al. Emerging cancer trends among young adults in the USA: analysis of a population-based cancer registry. Lancet Public Health 2019; 4: e137-e147
  • 13 Nannini DR, Joyce BT, Zheng Y. et al. Epigenetic age acceleration and metabolic syndrome in the coronary artery risk development in young adults study. Clin Epigenetics 2019; 11: 160
  • 14 Bagnati M, Ogunkolade BW, Marshall C. et al. Glucolipotoxicity initiates pancreatic beta-cell death through TNFR5/CD40-mediated STAT1 and NF-kappaB activation. Cell Death Dis 2016; 7: e2329
  • 15 Rohner M, Heiz R, Feldhaus S. et al. Hepatic-metabolite-based intermittent fasting enables a sustained reduction in insulin resistance in type 2 diabetes and metabolic syndrome. Horm Metab Res 2021; 53: 529-540
  • 16 Vistisen D, Witte DR, Tabak AG. et al. Patterns of obesity development before the diagnosis of type 2 diabetes: the Whitehall II cohort study. PLoS Med 2014; 11: e1001602
  • 17 Wu S, Fisher-Hoch SP, Reninger B. et al. Metabolic health has greater impact on diabetes than simple overweight/obesity in Mexican Americans. J Diabetes Res 2016; 4094876
  • 18 Eckel N, Li Y, Kuxhaus O. et al. Transition from metabolic healthy to unhealthy phenotypes and association with cardiovascular disease risk across BMI categories in 90 257 women (the Nurses’ Health Study): 30 year follow-up from a prospective cohort study. Lancet Diabetes Endocrinol 2018; 6: 714-724
  • 19 De Rosa V, Galgani M, Santopaolo M. et al. Nutritional control of immunity: Balancing the metabolic requirements with an appropriate immune function. Semin Immunol 2015; 27: 300-309
  • 20 Chavez-Reyes J, Escarcega-Gonzalez CE, Chavira-Suarez E. et al. Susceptibility for some infectious diseases in patients with diabetes: the key role of glycemia. Front Public Health 2021; 9: 559595
  • 21 Jensen AV, Faurholt-Jepsen D, Egelund GB. et al. Undiagnosed diabetes mellitus in community-acquired pneumonia: a prospective cohort study. Clin Infect Dis 2017; 65: 2091-2098
  • 22 Luzi L, Radaelli MG. Influenza and obesity: its odd relationship and the lessons for COVID-19 pandemic. Acta Diabetol 2020; 57: 759-764
  • 23 van Liempd S, Cabrera D, Pilzner C. et al. Impaired beta-oxidation increases vulnerability to influenza A infection. J Biol Chem 2021; 297: 101298
  • 24 Hoffmann M, Kleine-Weber H, Schroeder S. et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 2020; 181: 271-280 e8
  • 25 Kuznetsova T, Cauwenberghs N. Determinants of circulating angiotensin-converting enzyme 2 protein levels in the general population. Eur J Intern Med 2021; 84: 104-105
  • 26 Chen M, Zhu B, Chen D. et al. COVID-19 may increase the risk of insulin resistance in adult patients without diabetes: a 6-month prospective study. Endocr Pract 2021; 27: 834-841
  • 27 McGovern AP, Thomas NJ, Vollmer SJ. et al. The disproportionate excess mortality risk of COVID-19 in younger people with diabetes warrants vaccination prioritisation. Diabetologia 2021; 64: 1184-1186
  • 28 de Boer E, Petrache I, Goldstein NM. et al. Decreased fatty acid oxidation and altered lactate production during exercise in patients with post-acute COVID-19 syndrome. Am J Respir Crit Care Med 2022; 205: 126-129